

AP20 Rec'd PCT/PTO 20 JUL 2006

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	US National Phase of PCT Application No. PCT/US2005/007365
Filing Date	I.A. March 7, 2005
First Named Inventor	David S. Lawrence
Art Unit	
Examiner Name	

307586892

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	US National Phase of PCT Application No. PCT/US2005/0070365 10/586892
				Filing Date	I.A. March 7, 2005
				First Named Inventor	David S. Lawrence
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	96700/1160

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	4	STAMATOYANNOPOULOS, G. "Control of Globin Gene Expression During Development and Erythroid Differentiation." Experimental Hematology, March 2005, vol. 33(3), pps. 259-271.			
	5	KEELING, KM. et al., "Clinically Relevant Aminoglycosides Can Suppress Disease-Associated Premature Stop Mutations in the IDUA and P53 cDNAs in a Mammalian Translation System." Journal of Molecular Medicine, June 2002, vol. 80(6), pps. 367-376.			
	6	PAREKH-OLMEDO, H. et al. "Gene Therapy Progress and Prospects: Targeted Gene Repair." Gene Therapy, vol. 12(8), pps. 639-646.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.